Paulex Bio Inc. is a biotechnology company headquartered in San Diego, California, focused on transformative treatments for type 1 and type 2 diabetes. Its lead approach targets beta cell regeneration through an oral administration.
Subscribe to see Paulex Bio Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Paulex Bio Inc. is a biotechnology company headquartered in La Jolla, United States. Its most recent funding round raised $18.5M in November 2025. Xcout tracks 5 named people at Paulex Bio Inc., including Miguel Sanjuan (CEO, Paulex Bio).
As of 17 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $18.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Paulex Bio Inc.'s closest competitors — see the full list of competitors and alternatives →
Endsulin, Inc. is a biotechnology company developing a liver-directed gene therapy for Type 1 Diabetes. Its proprietary technology aims to re-engineer liver cells to restore the body's natural ability to produce and regulate insulin, eliminating the need for artificial insulin delivery methods.
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Tr1X is a private, clinical-stage biotechnology company focused on developing regulatory T cell-based products for autoimmune and inflammatory diseases. The company aims to advance Tr1-based immunotherapies to address unmet medical needs and is headquartered in San Diego, California.
Imagine Pharma LLC is a biotechnology company that develops novel polypeptide-based platforms focused on oral delivery for biologic drugs, therapeutics for various disease states, and regenerative medicine. The company aims to create first-in-class treatments for conditions such as diabetes and wound healing, alongside offering oral peptide dietary supplements and functional ingredients for consumers.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Paulex Bio Inc.? Suggest a correction · Work at Paulex Bio Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.